Valiant Laboratories Ltd. (VALIANTLAB) AI Stock Analysis

• Market Cap: ₹4.51B
• Dividend Yield: N/A
• Average Volume (3M): 3.75K
• Price to Earnings (P/E): 3018.2
• Beta (1Y): 0.78
• Revenue Growth: 7.88%
• EPS Growth: N/A
• Country: IN
• Employees: 77
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.39
• Shares Outstanding: 54,312,500
• 10 Day Avg. Volume: 998
• 30 Day Avg. Volume: 3,749
• PEG Ratio: 0.22
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 2.47
• P/FCF Ratio: -3.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ₹84.00 ▲(1.25% Upside)

Valiant Laboratories Ltd. faces significant financial challenges, with declining revenue and profitability, increased leverage, and cash flow issues. The technical analysis indicates a bearish trend, and the stock appears overvalued with an extremely high P/E ratio. These factors contribute to a low overall stock score.

Valiant Laboratories Ltd. Business Overview & Revenue Model

Company Description

Valiant Laboratories Ltd. (VALIANTLAB) is a leading biotechnology company focused on developing innovative solutions in the fields of healthcare and pharmaceuticals. The company specializes in the research, development, and manufacturing of high-quality laboratory reagents, diagnostic kits, and biopharmaceutical products. With a commitment to advancing medical science, VALIANTLAB operates in various sectors, including molecular biology, immunology, and clinical diagnostics, offering a wide range of products that cater to both research institutions and healthcare providers.

How the Company Makes Money

Valiant Laboratories Ltd. generates revenue through multiple key streams. The primary source of income comes from the sale of its laboratory reagents and diagnostic kits, which are supplied to research institutions, hospitals, and laboratories globally. The company also earns revenue from the development and commercialization of biopharmaceutical products, which may include licensing agreements and partnerships with larger pharmaceutical firms for co-development. Additionally, VALIANTLAB may engage in contract manufacturing services for other biotechnology companies, providing a steady income stream. Significant partnerships with healthcare providers and research organizations further enhance its market reach and contribute to consistent revenue growth.

Valiant Laboratories Ltd. Financial Statement Overview

Summary

Valiant Laboratories Ltd. is facing significant financial challenges. The income statement reveals declining revenue and profitability, with a negative net profit margin. The balance sheet shows increased leverage and negative returns on equity. Cash flow issues are severe, with negative free cash flow and low cash conversion efficiency.

Income Statement

Valiant Laboratories Ltd. has experienced declining revenue over the past two years, with a significant drop in revenue growth rate from 2023 to 2025. The gross profit margin has decreased, indicating pressure on cost management. The net profit margin turned negative in 2025, reflecting challenges in maintaining profitability. The EBIT and EBITDA margins have also deteriorated, suggesting operational inefficiencies or increased costs.

Balance Sheet

The company's debt-to-equity ratio has increased over the years, indicating a rising reliance on debt financing. However, the equity ratio remains stable, suggesting a balanced capital structure. Return on equity has turned negative in 2025, highlighting challenges in generating returns for shareholders. Despite these issues, the company maintains a relatively stable asset base.

Cash Flow

Valiant Laboratories Ltd. faces significant challenges in cash flow management, with a negative free cash flow in recent years. The free cash flow to net income ratio is highly negative, indicating inefficiencies in converting earnings into cash. The operating cash flow to net income ratio is low, reflecting difficulties in generating cash from operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	1.59B	1.39B	1.82B	3.34B	2.92B	1.82B
Gross Profit	217.45M	222.17M	115.76M	565.90M	523.21M	583.90M
EBITDA	49.59M	7.55M	-85.98M	399.53M	442.67M	514.14M
Net Income	1.29M	-22.01M	3.20M	289.98M	274.96M	305.93M
Balance Sheet
Total Assets	0.00	4.01B	3.43B	2.13B	1.82B	1.06B
Cash, Cash Equivalents and Short-Term Investments	759.91M	759.91M	1.44B	353.61M	205.33M	189.37M
Total Debt	0.00	1.22B	767.08M	602.17M	611.26M	6.04M
Total Liabilities	-2.34B	1.67B	1.06B	1.12B	1.10B	177.32M
Stockholders Equity	2.34B	2.34B	2.37B	1.00B	714.60M	885.82M
Cash Flow
Free Cash Flow	-1.13B	-1.13B	-439.85M	183.70M	-46.25M	74.40M
Operating Cash Flow	13.13M	13.13M	18.85M	560.51M	22.51M	91.09M
Investing Cash Flow	-527.68M	-527.68M	-1.44B	-551.68M	-122.38M	-166.69M
Financing Cash Flow	446.53M	446.53M	1.52B	-9.34M	61.81M	114.30M

Valiant Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 82.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Negative. The current price of 82.96 is below the 20-day moving average (MA) of 84.45, below the 50-day MA of 85.18, and below the 200-day MA of 91.28, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 24.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VALIANTLAB.

Valiant Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	―	₹1.87B	7.12	―	―	5.12%	38.44%
BIOFILCHEM	―	₹644.44M	23.02	―	―	-31.82%	341.44%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VALIANTLAB	―	₹4.51B	3,018.18	―	―	7.88%	―
LASA	―	₹585.18M	-1.77	―	―	25.82%	-69.86%
KREBSBIO	―	₹1.53B	-5.63	―	―	-31.91%	-38.46%
VIVIMEDLAB	―	₹406.28M	―	―	―	-24.33%	52.06%

Valiant Laboratories Ltd. Corporate Events

Valiant Laboratories Announces 4th AGM and Annual Report Release

Valiant Laboratories Limited has announced its 4th Annual General Meeting (AGM) scheduled for September 25, 2025, which will be conducted via video conferencing. The company has released its Annual Report for the financial year 2024-25, highlighting its strategic initiatives and operational achievements, which are accessible on their website. This announcement underscores Valiant Laboratories’ commitment to transparency and stakeholder engagement, potentially impacting its industry positioning and investor relations.

Valiant Laboratories Enhances Shareholder Communication for Upcoming AGM

Valiant Laboratories Ltd. has announced the dispatch of letters to shareholders who have not registered their email addresses, providing them with a web-link to access the Annual Report for the Financial Year 2024-25 and the Notice of the 4th Annual General Meeting. This initiative is part of the company’s efforts to ensure transparency and compliance with SEBI regulations, enhancing communication with stakeholders and facilitating their participation in the AGM through virtual means.